Sanofi extended a license for its STAT6 program, while the FDA cleared an IND application for an IRAK4 degrader, and Gilead initiated a Phase 1 trial collaboration.

The entities involved

• Sanofi →

  company in Milan, Italy

  • Sanofi advances Kymera's degrader candidate.Wed 19:26
• FDA →
  • The FDA approved Miplyffa for the treatment of Niemann-Pick disease.Sat 00:55
  • iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Fri 23:50
• Gilead Sciences →

  American company

  • FDA approved lenacapavir (Yeztugo) on August 18, 2025, solidifying the HIV portfolio for Gilead Sciences.Mon 18:04
  • Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32

Related events

• BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.Oct 30
• Gilead Sciences supplied sacituzumab govitecan for a clinical trial on October 22, 2026.Oct 22